Female Infertility Treatment Segment Type Accounted for Highest Revenue during the Prediction Period
Human chorionic gonadotropin (hCG) sales may be broken down by product type, application, and geographic location throughout the world. The market may be classified into natural source extraction and recombinant technology, based on the method used to extract it. The market may be divided into male hypogonadism, female infertility therapy, oligospermic treatment, and other subcategories based on their uses. Among them, the human chorionic gonadotropin market is dominated by treatments for female infertility.
Human chorionic gonadotropin (hcG) hormone demand is increasing in developing nations because to the availability of therapy and services for infertility and a rise in knowledge of therapies for infertility difficulties. Human chorionic gonadotropin (hCG) market growth is primarily driven by the increasing frequency of hypogonadism-related illnesses in males, particularly in older men. There is a growing demand for hCG due to the efforts of global health organizations and non-profit organizations to improve the sexual health of individuals in developing nations. As a result of their sedentary lifestyle and stress connected to their personal and professional lives, many women are experiencing fertility-related difficulties. Women living in urban areas are more likely to seek medical attention for conditions that affect their quality of life. Human chorionic gonadotropin (hCG) market expansion is being fueled by the increasing number of elderly women. Human chorionic gonadotropin (hcG) market growth is expected to be restrained in the near future by the FDA's warnings about the negative effects of using hcG as therapy, although this is expected to change in the near future.
North American Region to Hold the Highest Revenues during the Predicted Period
Based on regions, the global human chorionic gonadotropin market is bifurcated into NA, EU, APAC, South America, & MEA. HCG is predicted to be the most popular therapy for infertility in North America and Europe because of the emphasis on new, sophisticated procedures and the existence of major pharmaceutical and biotechnology organizations in the countries. Over the forecast period, the Asia-Pacific hCH market is expected to develop at a quick pace. Growth in the hCG market is being fueled by a growing patient population and a growing public awareness of health care treatment options and services.
Rising incidence of infertility to drive human chorionic gonadotropin market growth
More than 8 million women aged 15 to 44 received infertility therapies in 2018, according to the CDC. Furthermore, approximately 6% of married women between the ages of 15 and 44 were found to be infertile. Approximately 17 percent of American couples are affected by infertility, with 30 percent of those instances attributed to male infertility. Infertility therapies, such as HCG, are in high demand by women in order to conceive a child. Pituitary gland problems claimed the lives of over 200+ persons in 2018, with the majority of those deaths occurring among white males. Human chorionic gonadotropin hormone is in high demand due to pituitary abnormalities that lead to a high death rate. Other causes including endometriosis, hormonal imbalance, polycystic ovary syndrome, and others are also predicted to drive the global HCG market's rise in the future. About 10% of women in their reproductive years in the United States are affected with polycystic ovarian syndrome, according to the Frisco Institute of Reproductive Medicine. Infertility treatment options are readily available, which may limit the market's development.
The changing lifestyles and poor dietary habits are key factors driving the growth of the global human chorionic gonadotropin market. Due to the surge in women's infertility, the worldwide Human Chorionic Gonadotropin (hCG) market has grown tremendously over the last several years. Changing lifestyles and bad nutritional habits are predicted to play a major role in the hCG market's increasing sales. Gynecology is the primary range of medicine that focuses on women's health. Conditions affecting the health and well-being of women are taken into consideration. Breast cancer, cervical cancer, & ovarian cancer are most common cancers seen among the women population across the globe. Infertility, polycystic ovarian disease, menopause, osteoporosis, depression, and obesity are all on the increase among women. In pregnant women, the placenta produces human chorionic gonadotropin, a kind of gonadotropin hormone.
The global human chorionic gonadotropin market is categorized based on product, and applications. Region wise, North America was the largest market in 2018; however, Asia Pacific is expected to be the fastest growing region by 2028, with a CAGR of over 8%.
Key players serving the global human chorionic gonadotropin market include Merck KGaA, Fresenius SE & Co. KGaA, Lupin Limited, Merck & Co. Inc., Sanzyme, Intas Pharmaceuticals, Minerva BC (Lee Biosciences), and Sun Pharmaceutical Industries Limited among other prominent players.
Latest Innovations in the Global Market: a Snapshot
- One of the most frequently researched indicators in embryo development is human chorionic gonadotropin (hCG) is collected from pregnant women's urine (uhCG) for almost three decades and is used to induce ovulation in women undergoing IVF therapy.
- The European Medicines Agency and state health authorities as well as certified entities regulate and oversee the manufacturing and quality of medicinal products for human and animal use in the European Union. Pharmaceutical and medical device manufacturers are required to adhere to stringent criteria and ensure that all activities are carried out in accordance with GMP and GLP regulations.
This market research study was created by compiling data from primary and secondary sources. Secondary research was conducted using a variety of sources, including (but not limited to) SEC filings, company websites, technical journals, paid data sources, financial reports, and other industry publications. In addition, to acquire first-hand data, the research methodologies perform comprehensive primary research with important industry players. Industry specialists then examine and validate the data.
Human Chorionic Gonadotropin Market Scope
|Forecast Unit||Value (USD)|
|Growth Rate||CAGR of 8% during 2021-2028|
|Segment Covered||Product, Application, Regions|
|Regions Covered||North America, Europe, Asia Pacific, South America, Middle East and South Africa|
|Key Players Profiled||Merck KGaA, Fresenius SE & Co. KGaA, Lupin Limited, Merck & Co. Inc., Sanzyme, Intas Pharmaceuticals, Minerva BC (Lee Biosciences), and Sun Pharmaceutical Industries Limited among other prominent players.|
Key segments of the global human chorionic gonadotropin market
Product Overview, 2018-2028 (USD Million)
- Natural Extraction
Applications Overview, 2018-2028 (USD Million)
- Male Hypogonadism
- Female Infertility Treatment
- Oligospermic Treatment
- Other Applications
Regional Overview, 2018-2028 (USD Million)
- North America
- United Kingdom
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- South Africa
- Rest of Middle East and Africa